Skip to content

Clinical effect and central response mechanism of acupuncture for hypertensive patients complicated with mild cognitive impairment from the perspective of collaterals

Clinical effect and central response mechanism of acupuncture for hypertensive patients complicated with mild cognitive impairment from the perspective of collaterals

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083501
Enrollment
Unknown
Registered
2024-04-26
Start date
2024-04-28
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension complicated with mild cognitive impairment

Interventions

acupuncture group:Acupoints: Baihui, Shenting, Neiguan, Ashansanli, Fenglong, Taichong Acupoint localization: refer to the national standard of the People's Republic of China "Acupoint Name and Locali

Sponsors

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Eligible participants should meet the following requirements: (1) Meet the diagnostic criteria of hypertension; (2) Meet the diagnostic criteria of MCI, ? Mini-Mental State Examination (MMSE)=21 points and<27 points; ?Montreal Cognitive Assessment Scale(MoCA) =18 points and < 26 points; ?Activity of daily living scale(ADL) <22 points, and no more than one item in the single score may be =3 points; (3) Age 40-75 years old, right-handed, male or female; (4) Primary school education (6 years) or above, able to correctly understand and complete the scale; (5) no acupuncture treatment has been received within 3 months; (6) Voluntarily cooperate and sign informed consent;

Exclusion criteria

Exclusion criteria: Participants meeting any of the following criteria will be excluded: (1) Individuals who have undergone treatments potentially interfering with cognitive functions, such as the use of cognition-impacting medications (e.g., Donepezil, Memantine, Rivastigmine); (2). Individuals diagnosed with neurological or chronic conditions, including systemic diseases (e.g., anemia, tumors, metabolic disorders) that could impair cognitive functions; (3) Presence of infection or focal injury, as indicated by brain MRI, multiple infarcts, or cerebral white matter lesions in critical memory areas (Fazekas Rating >3); (4) Individuals with secondary hypertension, refractory hypertension, or hypertension accompanied by clinical syndromes and target organ damage; (5)Individuals experiencing aphasia, hearing impairment, muscle strength functional impairment below grade 3, severe visual impairment, or myopia exceeding 300, rendering them unable to cooperate with the test; (6)Patients with coexisting diabetes, hyperlipidemia, or a body mass index (BMI) 35); (8) Individuals with hemorrhagic conditions, bleeding tendencies, infectious skin diseases, or skin injuries; (9) Individuals with severe drug dependence, smoking, or alcoholism; (10) Women who are menstruating, pregnant, planning pregnancy or breastfeeding; (11)Individuals who have received acupuncture treatment or participated in other clinical trials within the past 3 months;

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment (MoCA);

Secondary

MeasureTime frame
Mini-Mental State Examination;Blood pressure condition;verbal fluency test, VFT;the shape trail test, STT;Auditory Verbal Learning Test;Activity of daily living, ADL;Hamilton Anxiety Scale;Pittsburgh Sleep Quality Index;mean velocity (Vm);resistance index (RI);pulse index (PI);Aß-42;BDNF;tau;

Countries

China

Contacts

Public ContactLili Zhang

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

zhanglili007@126.com+86 136 6209 3820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026